Explaining adverse cholesterol levels and distinct gender patterns in an Indonesian population compared with the U.S
- PMID: 38861883
- PMCID: PMC11330738
- DOI: 10.1016/j.ehb.2024.101403
Explaining adverse cholesterol levels and distinct gender patterns in an Indonesian population compared with the U.S
Abstract
Cardiovascular disease is among the most common causes of death around the world. As rising incomes in low and middle-income countries are accompanied by increased obesity, the burden of disease shifts towards non-communicable diseases, and lower-income settings make up a growing share of cardiovascular disease deaths. Comparative investigation of the roles of body composition, behavioral and socioeconomic factors across countries can shed light on both the biological and social drivers of cardiovascular disease more broadly. Comparing rigorously-validated measures of HDL and non-HDL cholesterol among adults in the United States and in Aceh, Indonesia, we show that Indonesians present with adverse cholesterol biomarkers relative to Americans, despite being younger and having lower body mass index. Adjusting for age, the gaps increase. Body composition, behaviors, demographic and socioeconomic characteristics that affect cholesterol do not explain between-country HDL differences, but do explain non-HDL differences, after accounting for medication use. On average, gender differences are inconsistent across the two countries and persist after controlling observed characteristics. Leveraging the richness of the Indonesian data to draw comparisons of males and females within the same household, the gender gaps among Indonesians are not explained for HDL cholesterol but attenuated substantially for non-HDL cholesterol. This finding suggests that unmeasured household resources play an important role in determining non-HDL cholesterol. More generally, they appear to be affected by social and biological forces in complex ways that differ across countries and potentially operate differently for HDL and non-HDL biomarkers. These results point to the value of rigorous comparative studies to advance understanding of cardiovascular risks across the globe.
Keywords: Biomarkers; Cardiovascular risks; Cholesterol; Indonesia; United States.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Sex differentials in biological risk factors for chronic disease: estimates from population-based surveys.J Womens Health (Larchmt). 2004 May;13(4):393-403. doi: 10.1089/154099904323087088. J Womens Health (Larchmt). 2004. PMID: 15186656
-
The impact of socioeconomic status on cardiovascular risk factors in African-Americans at high risk for type II diabetes. Implications for syndrome X.Diabetes Care. 1997 May;20(5):745-52. doi: 10.2337/diacare.20.5.745. Diabetes Care. 1997. PMID: 9135936
-
Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study).Am J Cardiol. 2003 Jun 1;91(11):1311-5. doi: 10.1016/s0002-9149(03)00319-9. Am J Cardiol. 2003. PMID: 12767422
-
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Vasc Health Risk Manag. 2013;9:617-70. doi: 10.2147/VHRM.S37119. Epub 2013 Oct 21. Vasc Health Risk Manag. 2013. PMID: 24174878 Free PMC article. Review.
-
High density lipoprotein cholesterol distribution and predictive power in some Italian populations studies.Eur J Epidemiol. 1989 Sep;5(3):328-35. doi: 10.1007/BF00144833. Eur J Epidemiol. 1989. PMID: 2676584 Review.
References
-
- Albert Michelle A., Glynn Robert J., Fonseca Francisco A.H., Lorenzatti Alberto J., Ferdinand Keith C., MacFadyen Jean G., Ridker Paul M. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Am. Heart J. 2011;162(1):106–114.e2. doi: 10.1016/j.ahj.2011.03.032. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials